Bliss GVS Pharma Ltd

Bliss GVS Pharma Ltd is rated Buy by MarketsMOJO, with this rating last updated on 13 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

At Rs 650.75, sellers were still queuing — but there were no buyers willing to take the other side. Bliss GVS Pharma Ltd locked at its lower circuit of 5.0% on 16 Sep 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a thinly traded small-cap stock.

At Rs 695, sellers were still queuing — but there were no buyers willing to take the other side. Bliss GVS Pharma Ltd locked at its lower circuit of 5% on 15 Sep 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a small-cap stock.

Bliss GVS Pharma Ltd is rated Buy by MarketsMOJO, with this rating last updated on 13 August 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 10 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market standing.

From a low of Rs 118.35 to a new peak of Rs 733.75, Bliss GVS Pharma Ltd has surged an extraordinary 355.61% over the past year, defying the broader market’s downward trend. This remarkable ascent culminated in a fresh 52-week high on 9 Sep 2026, driven predominantly by a confluence of bullish technical indicators and sustained price momentum.

Bliss GVS Pharma Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 09 September 2026, with its stock price touching an all-time high of Rs.733.75. This achievement reflects the company’s robust performance and sustained growth over recent years.

From a 52-week low of Rs 118.35 to a new peak of Rs 720, Bliss GVS Pharma Ltd has surged an extraordinary 354.49% in the past year, defying the broader market’s downward trend. This remarkable rally is underpinned by a confluence of strong technical indicators and sustained price momentum that have propelled the stock to fresh highs despite a weakening Sensex.

Bliss GVS Pharma Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 8 September 2026 by touching its all-time high price of Rs.720. This achievement reflects the company’s robust performance and sustained upward momentum in the stock market.

At Rs 685.0, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Bliss GVS Pharma Ltd locked at its upper circuit of 5% on 7 Sep 2026, with buyers queuing and no sellers willing to part with shares.

Surging past its previous peaks, Bliss GVS Pharma Ltd touched a fresh 52-week high of Rs 702.1 on 7 Sep 2026, marking a remarkable rally from its low of Rs 118.35 just a year ago. This extraordinary price momentum is underpinned by a confluence of bullish technical indicators and sustained upward price action, setting the stage for a compelling momentum story in the pharmaceuticals sector.

Bliss GVS Pharma Ltd has reached a significant milestone by touching an all-time high price of Rs.702.10 on 07 Sep 2026, reflecting a robust performance in the Pharmaceuticals & Biotechnology sector. This achievement underscores the company’s sustained growth trajectory and strong market positioning over recent years.

At Rs 607.4, sellers were still queuing — but there were no buyers willing to take the other side. Bliss GVS Pharma Ltd locked at its lower circuit of 5.55% on 4 Sep 2026, with unfilled sell orders and a frozen price, signalling a pronounced imbalance between supply and demand.

Surging to an all-time high of Rs 670.5 on 3 Sep 2026, Bliss GVS Pharma Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market with a 316.64% gain over the past year. This milestone caps a sustained rally fuelled by a confluence of bullish technical indicators and robust trading volumes.

Bliss GVS Pharma Ltd has reached a significant milestone by touching an all-time high price of Rs.660 on 3 September 2026, marking a remarkable phase in the company’s market journey. This achievement reflects the company’s strong performance across multiple financial and technical parameters, underscoring its resilience and growth in the Pharmaceuticals & Biotechnology sector.

A 304.02% stock return in one year. A 29.1% growth in net profit over the same period. The gap between those two numbers — roughly 275 percentage points — is driven entirely by the market's willingness to pay more for each rupee of Bliss GVS Pharma Ltd's earnings. That willingness is the story.

Surging to an all-time high of Rs 639.95 on 2 Sep 2026, Bliss GVS Pharma Ltd has demonstrated remarkable price momentum, outperforming the broader market by a wide margin over the past year. This milestone caps a spectacular rally from its 52-week low of Rs 118.35, representing a staggering 293.01% gain, even as the Sensex has declined by 4.74% during the same period.

After a remarkable rally that has seen Bliss GVS Pharma Ltd surge over 285% in the past year, the stock touched a fresh all-time high of Rs 639.95 on 2 Sep 2026, underscoring its strong momentum despite a slight pullback on the day.